SCHEMBL4425699

SCHEMBL4425699

COc1cc2c(c(OC)c1)C(c1cccc(OC(F)(F)F)c1)N(S(=O)(=O)c1ccc(NC(C)=O)c(Cl)c1)CC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 2/20 0.41
LMNA P02545 3/20 0.40
ALDH1A1 P00352 2/20 0.39
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39
TUBB3 Q13509 1/20 0.39
TUBB2A Q13885 1/20 0.39
TUBB8 Q3ZCM7 1/20 0.39
TUBA3E Q6PEY2 1/20 0.39
TUBA1A Q71U36 1/20 0.39
TUBA1C Q9BQE3 1/20 0.39
TUBB6 Q9BUF5 1/20 0.39
TUBB2B Q9BVA1 1/20 0.39
TUBB1 Q9H4B7 1/20 0.39
ACHE P22303 2/20 0.39
NPSR1 Q6W5P4 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4415220 0.85 ALDH1A1 (0.44) TAS2R14LMNAALDH1A1TUBB4ATUBB
SCHEMBL4552332 0.84 TAS2R14 (0.49) TAS2R14LMNAALDH1A1NPSR1L3MBTL1
SCHEMBL13972857 0.84 TAS2R14 (0.49) TAS2R14LMNAALDH1A1NPSR1L3MBTL1
SCHEMBL4414803 0.84 VCAM1 (0.41) TAS2R14LMNANPSR1L3MBTL1
SCHEMBL4416979 0.82 TAS2R14 (0.46) TAS2R14NPSR1L3MBTL1MMP9MMP2
SCHEMBL4424185 0.81 LMNA (0.42) LMNAALDH1A1TUBB4ATUBBTUBA3C
SCHEMBL4410698 0.81 NPSR1 (0.41) TAS2R14LMNANPSR1TSHRL3MBTL1
SCHEMBL4414695 0.80 CA1 (0.49) TAS2R14LMNAALDH1A1ACHENPSR1
SCHEMBL4415190 0.80 CA1 (0.41) TAS2R14NPSR1L3MBTL1HCRTR1HCRTR2
SCHEMBL13972687 0.80 ALDH1A1 (0.37) TAS2R14LMNAALDH1A1ACHENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663983-B1 N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS 4SC AG (DE) 2009-01-21 EP disclosed
EP-1663983-A1 N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS 4SC AG (DE) 2006-06-07 EP disclosed
US-20050070570-A1 Novel potassium channels modulators 4SC AG (DE) 2005-03-31 US disclosed
WO-2004113302-A1 N-SUBSTITUTED 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS 4SC AG (DE) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070570-A1 Novel potassium channels modulators HCN4, KCNA4, KCNN4 TAS2R14 514/4885LMNA 4519/4885ALDH1A1 3171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.